Literature DB >> 8435334

Antibody By114 is selective for the 90 kD PI-linked component of the CD66 antigen: a new reagent for the study of paroxysmal nocturnal haemoglobinuria.

K M Mayne1, K Pulford, M Jones, K Micklem, G Nagel, C E van der Schoot, D Y Mason.   

Abstract

This paper describes a monoclonal antibody which reacts with transfected cells carrying a gene (NCA-50/90) which has been shown to encode the human CD66 antigen. However, antibody By114 recognizes only a single 90 kD polypeptide from human neutrophils, whereas the antibodies which originally defined the CD66 antigen also recognize a larger 180-200 kD protein. We conclude that antibody By114 is selective for the smaller of the two CD66 gene products, which is a surface membrane phosphatidyl-inositol (PI)-linked molecule. The reactivity of antibody By114 on peripheral blood cells (positive on neutrophils, weak or negative on eosinophils, and negative on basophils, monocytes and lymphocytes) and myeloid precursor cells was identical to those of a reference CD66 antibody, as was the staining of leukaemic cells. However, the reactions of the two antibodies differed on kidney, liver and pancreas, and in cases of myeloma, Waldenström's macroglobulinaemia and lymphoma, indicating that By114 represents a new CD66 sub-specificity. Granulocytes from a case of paroxysmal nocturnal haemoglobinuria (PNH) were negative with antibody By114, indicating that it may be of value in detecting the defect in PI-linked surface molecules characteristic of this condition. Antibody By114 also stained formalin fixed paraffin embedded tissues and may therefore be of use in routine diagnostic histopathology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435334     DOI: 10.1111/j.1365-2141.1993.tb04627.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions.

Authors:  Mark S Duxbury; Evan Matros; Thomas Clancy; Gerald Bailey; Michael Doff; Michael J Zinner; Stanley W Ashley; Anirban Maitra; Mark Redston; Edward E Whang
Journal:  Ann Surg       Date:  2005-03       Impact factor: 12.969

Review 2.  Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor.

Authors:  E T Yeh; W F Rosse
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

3.  Expression of CD66a in multiple myeloma.

Authors:  Yukihiko Satoh; Toshiaki Hayashi; Tohru Takahashi; Fumio Itoh; Masaaki Adachi; Mikiko Fukui; Motomu Kuroki; Masahide Kuroki; Kohzoh Imai; Yuji Hinoda
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

4.  A novel internal antigen which distinguishes germinal centre cells from other B-cell types.

Authors:  K Pulford; K J Micklem; M Jones; F Pezzella; K M Mayne; H Morrison; J Thomas; B Falini; A Norton; D Y Mason
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

5.  Several carcinoembryonic antigens (CD66) serve as receptors for gonococcal opacity proteins.

Authors:  T Chen; F Grunert; A Medina-Marino; E C Gotschlich
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

6.  Therapeutic Effect of pHLIP-mediated CEACAM6 Gene Silencing in Lung Adenocarcinoma.

Authors:  Seung-Myoung Son; Jieun Yun; Sung-Hoon Lee; Hye Sook Han; Young Hyun Lim; Chang Gok Woo; Ho-Chang Lee; Hyung Geun Song; Young-Mi Gu; Hyun-Jun Lee; Ok-Jun Lee
Journal:  Sci Rep       Date:  2019-09-02       Impact factor: 4.379

7.  Synthetic peptides from the N-domains of CEACAMs activate neutrophils.

Authors:  K M Skubitz; K D Campbell; A P Skubitz
Journal:  J Pept Res       Date:  2001-12

8.  Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies.

Authors:  Benny Johnson; Daruka Mahadevan
Journal:  Clin Cancer Drugs       Date:  2015-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.